The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Open accessAbstract
PURPOSE: SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma and report the results of the osteosarcoma cohort. PATIENTS AND METHODS: This trial enrolled patients with progressive metastatic osteosarcoma with measurable disease by RECIST who had received at least one prior line of therapy. Patients were randomly assigned at a ratio of one to one to regorafenib or placebo. Crossover was allowed at time of disease progression. PFS was the primary end point of the study, which was powered to detect a difference of at least 3 months in median PFS. RESULTS: Forty-two patients from 12 centers were enrolled between September 2014 and May 2018. Median age was 37 years (range, 18 to 76 years). Patients had received an average of 2.3 prior therapy regimens. Ten patients receiving placebo crossed over to active drug at time of progression. Study enrollment was stopped early, after a data safety monitoring committee review. Median PFS was significantly improved with regorafenib versus placebo: 3.6 months (95% CI, 2.0 to 7.6 months) versus 1.7 months (95% CI, 1.2 to 1.8 months), respectively (hazard ratio, 0.42; 95% CI, 0.21 to 0.85; P = .017). In the context of the crossover design, there was no statistically significant difference in overall survival. Fourteen (64%) of 22 patients initially randomly assigned to regorafenib experienced grade 3 to 4 events attributed to treatment, including one grade 4 colonic perforation. CONCLUSION: The study met its primary end point, demonstrating activity of regorafenib in patients with progressive metastatic osteosarcoma. No new safety signals were observed. Regorafenib should be considered a treatment option for patients with relapsed metastatic osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, clinical trials involving TKIs alone are typically with median PFS ranging from 4 to 6 months accompanied with inevitable development of secondary drug resistance1–5.”
From Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, PFS data for IE in relapsed or refractory osteosarcoma were published several decades before the OLIE study46; thus, the PFS estimate for IE relied on limited historical data from other clinically active agents,15,35,36 and IE performed better than expected relative to these assumptions.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“demonstrating a median progression‐free survival (PFS) of 14.8 weeks in Ewing sarcoma, 10 a median PFS of 3.6 months in osteosarcoma, 11 and a nonprogressive rate at 3 months of 54%, significantly better than results with placebo in chondrosarcoma. 12”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have demonstrated that multi-targeted tyrosine kinase inhibitor (TKIs) can induce varying degrees of objective responses and prolong progression-free survival (PFS)1–5.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“BS on average show very low TMB: 0.79–1.96 mutations/Mbase in osteosarcoma, 11 , 17 , 18 , 19 ∼0.2 mutations/Mbas in Ewing sarcoma 19 , 20 and <5 mutations/Mbase in chondrosarcoma with some correlation with grade. 21”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [11]
Experimental — accuracy not yet measured
In the citing paper
“Objective response rates were low at 10-15%.”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Of note, dose interruptions and reductions of MTKIs have been frequent across these trials secondary to common toxic effects of this drug class, including hand-foot rash syndrome (palmar-plantar erythrodysesthesia), gastrointestinal toxic effects and hypertension 146,147,148,149,150,151 .”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Four-month progression-free survival (PFS) ranged from 35% to 70% 146,147,148,149,151 .”
From Osteosarcoma (2022) · cites this paper as [146]
In the citing paper
“Prospective clinical trials evaluated the MTKIs sorafenib, regorafenib, cabozantinib, lenvatinib and apatinib as single agents in patients with relapsed or refractory osteosarcoma, with most enrolled patients falling in the adult age range 146,147,148,149,150,151 (Table 2).”
From Osteosarcoma (2022) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 2×
“Six of 22 patients in SARC028 achieved stable disease, resulting in 12-week PFS of 32%, suggesting activity worth further evaluation of immune checkpoint inhibitors in osteosarcoma.(21) Time Since Start of Crossover Treatment (months) C”
BackgroundSelf-citationLink, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
Osteosarcoma, Chondrosarcoma, and Chordoma
Whelan, J., & Davis, L. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1743 · Cited by 477
Self-citationBielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 372
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Grignani, G., Palmerini, E., Ferraresi, V., D’Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 343
Cited by
Sorted by citations
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
New Horizons in the Treatment of Osteosarcoma
Meltzer, P. S., & Helman, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2103423 · Cited by 672
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Rédiní, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 494
Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E., Chevreau, C., Duffaud, F., Entz-Werlé, N., Saada, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30825-3 · Cited by 326
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 300
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Harris, M. A., & Hawkins, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073817 · Cited by 148
Suehara, Y., Alex, D., Bowman, A., Middha, S., Zehir, A., Chakravarty, D., Wang, L., Jour, G., Nafa, K., Hayashi, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4032 · Cited by 135
Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies
Rathore, R., & Tine, B. A. V. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061182 · Cited by 129
Recent progress in the treatment of cancer in children
Butler, E. B., Ludwig, K. F., Pacenta, H. L., Klesse, L. J., Watt, T. C., & Laetsch, T. W. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21665 · Cited by 130
Evolving role of regorafenib for the treatment of advanced cancers
Grothey, A. F., Blay, J., Pavlakis, N., Yoshino, T., & Bruix, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101993 · Cited by 116
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Boye, K., Longhi, A., Guren, T., Lorenz, S., Næss, S., Pierini, M., Taksdal, I., Lobmaier, I., Cesari, M., Paioli, A., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-02876-w · Cited by 112
Mascarenhas, L., Chi, Y.-Y., Hingorani, P., Anderson, J. R., Lyden, E. R., Rodeberg, D. A., Indelicato, D. J., Kao, S. C.-S., Dasgupta, R. A., Spunt, S. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00576 · Cited by 111
Self-citationTargeted therapy for osteosarcoma: a review
Li, S., Zhang, H., Liu, J., & Shang, G. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04614-4 · Cited by 107
Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma
Anand, N., Peh, K. H., & Kolesar, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032858 · Cited by 94
Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy
Zhao, J., Dean, D. C., Hornicek, F. J., Yu, X., & Duan, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.020 · Cited by 92
Liu, K., Liao, Y., Zhou, Z., Zhang, L., Jiang, Y., Lu, H., Xu, T., Dong, Y., Gao, Q., Li, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121383 · Cited by 90
Gaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89
Recent Insights into Therapy Resistance in Osteosarcoma
Prudowsky, Z. D., & Yustein, J. T. (2020) · Cancers · doi:10.3390/cancers13010083 · Cited by 89
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Tian, Z., Niu, X., & Yao, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01642 · Cited by 87
An overview of resistance to chemotherapy in osteosarcoma and future perspectives
García-Ortega, D. Y., Cabrera-Nieto, S. A., Caro-Sánchez, C. H. S., & Cruz‐Ramos, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.18 · Cited by 90
Origin and Therapies of Osteosarcoma
Moukengué, B., Lallier, M., Marchandet, L., Baud’huin, M., Verrecchia, F., Ory, B., & Lamoureux, F. (2022) · Cancers · doi:10.3390/cancers14143503 · Cited by 93
Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma
Liu, Y., Huang, N., Liao, S., Rothzerg, E., Yao, F., Li, Y., Wood, D., & Xu, J. (2021) · Cell Proliferation · doi:10.1111/cpr.13102 · Cited by 76
Dzamukova, M. R., Brunner, T. M., Miotla‐Zarebska, J., Heinrich, F., Brylka, L., Mashreghi, M., Kusumbe, A. P., Kühn, R., Schinke, T., Vincent, T. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30618-8 · Cited by 74
Current Status and Prospects of Targeted Therapy for Osteosarcoma
Hu, Z., Wen, S., Huo, Z., Wang, Q., Zhao, J., Wang, Z., Chen, Y., Zhang, L., Zhou, F., Guo, Z., et al. (2022) · Cells · doi:10.3390/cells11213507 · Cited by 78
Osteosarcoma: Current Concepts and Evolutions in Management Principles
Pilavaki, P., Ardakani, A. H. G., Gikas, P. D., & Constantinidou, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082785 · Cited by 70
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Biermann, J. S., Hirbe, A. C., Ahlawat, S., Bernthal, N. M., Binitie, O. T., Boles, S. G., Brigman, B. E., Callan, A. K., Cipriano, C. A., Cranmer, L. D., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0017 · Cited by 67
An update on emerging drugs in osteosarcoma: towards tailored therapies?
Hattinger, C. M., Patrizio, M. P., Magagnoli, F., Luppi, S., & Serra, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1654455 · Cited by 67
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63
Targeting the VEGF Pathway in Osteosarcoma
Assi, T., Watson, S., Samra, B., Rassy, E., Cesne, A. L., Italiano, A., & Mir, O. (2021) · Cells · doi:10.3390/cells10051240 · Cited by 62
The roles of glycolysis in osteosarcoma
Feng, Z., Ou, Y., & Hao, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.950886 · Cited by 60
Gaspar, N., Campbell-Hewson, Q., Gallego Melcon, S., Locatelli, F., Venkatramani, R., Hecker-Nolting, S., Gambart, M., Bautista, F., Thebaud, E., Aerts, I., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100250 · Cited by 59
E, E. R. P., Antonescu, C. R., Smith, S. A., Bradić, M., Kashani, D., Richards, A. L., Donoghue, M. T. A., Kelly, C. M., Nacev, B. A., Chan, J. E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004149 · Cited by 58
Rathore, R., Caldwell, K. E., Schutt, C. R., Brashears, C. B., Prudner, B. C., Ehrhardt, W. R., Leung, C. H., Lin, H. Y., Daw, N. C., Beird, H. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108678 · Cited by 52
Rare Primary Malignant Bone Sarcomas
Palmerini, E., Righi, A., & Staals, E. L. (2020) · Cancers · doi:10.3390/cancers12113092 · Cited by 47
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements
Adewuyi, E. E., Chorya, H. P., Muili, A. O., Moradeyo, A. A., Kayode, A. T., Naik, A., Odedele, J. T., & Obasanjo, O. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104575 · Cited by 42
Fleuren, E. D. G., Vlenterie, M., & van der Graaf, W. T. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1013359 · Cited by 41
Zhang, H., Wang, T., Gong, H., Jiang, R., Wang, Z., Sun, H., Huang, R., Wang, Y., Wu, Z., Xu, W., et al. (2023) · Bone Research · doi:10.1038/s41413-022-00233-w · Cited by 41
The diagnosis and treatment of osteosarcoma and Ewing’s sarcoma in children and adolescents
Zarghooni, K., Bratke, G., Landgraf, P., Simon, T., Maintz, D. C., & Eysel, P. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0079 · Cited by 40
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
Albarrán, V., Villamayor, M. L., Chamorro, J., Rosero, D. I., Pozas, J., Román, M. S., Calvo, J. C., de Aguado, P. P., Moreno, J. A., Guerrero, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213784 · Cited by 37
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials
Tang, F., Tie, Y., Wei, Y.-Q., Tu, C., & Wei, X. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188606 · Cited by 39
Palmerini, E., Setola, E., Grignani, G., D’Ambrosio, L., Comandone, A., Righi, A., Longhi, A., Cesari, M., Paioli, A., Hakim, R., et al. (2020) · Cells · doi:10.3390/cells9112389 · Cited by 36
Díaz, E. C. G., Lee, A. G., Sayles, L. C., Feria, C., Sweet-Cordero, A., & Yang, F. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200768 · Cited by 35
Zhang, N., Zhang, S., Wu, W., Lu, W., Jiang, M., Zheng, N., Huang, J., Wang, L., Liu, H., Zheng, M., et al. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23279 · Cited by 35
Bouhamama, A., Leporq, B., Khaled, W., Nemeth, A., Brahmi, M., Dufau, J., Marec‐Bérard, P., Drapé, J., Gouin, F., Bertrand-Vasseur, A., et al. (2022) · Radiology Imaging Cancer · doi:10.1148/rycan.210107 · Cited by 35
Targeting the Lysosomal Degradation of Rab22a‐NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis
Zeng, C., Zhong, L., Liu, W., Zhang, Y., Yu, X., Wang, X., Zhang, R., Kang, T., & Liao, D. (2022) · Advanced Science · doi:10.1002/advs.202205483 · Cited by 37
Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
Brown, L. M., Ekert, P. G., & Fleuren, E. D. G. (2023) · Oncogene · doi:10.1038/s41388-023-02705-7 · Cited by 37
Practical considerations in the use of regorafenib in metastatic colorectal cancer
Loupakis, F., Antonuzzo, L., Bachet, J., Kuan, F., Macarulla, T. M., Pietrantonio, F., Xu, R., Taniguchi, H., Winder, T. L., Yuki, S., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920956862 · Cited by 33
The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment
Zając, A. E., Czarnecka, A. M., & Rutkowski, P. L. (2023) · Cancers · doi:10.3390/cancers15215294 · Cited by 32
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
Yan, P., Wang, J., Yue, B., & Wang, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189171 · Cited by 31
Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities
Du, X., Wei, H., Zhang, B., Wang, B., Li, Z., Pang, L. K., Zhao, R., & Yao, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117867 · Cited by 31
van Ewijk, R., Herold, N., Baecklund, F., Baumhoer, D., Boye, K., Gaspar, N., Harrabi, S., Haveman, L., Hecker‐Nolting, S., Hiemcke‐Jiwa, L. S., et al. (2023) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2023.100029 · Cited by 33
Chiabotto, G., Grignani, G., Todorovic, M., Martín, V., Centomo, M. L., Prola, E., Giordano, G. D., Merlini, A., Miglio, U., Berrino, E., et al. (2020) · Cancers · doi:10.3390/cancers12061519 · Cited by 30
Role of TKI for Metastatic Osteogenic Sarcoma
Duffaud, F. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00760-w · Cited by 30
Schott, C. R., Shah, A. T., & Sweet-Cordero, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_1 · Cited by 30
Palmerini, E., Lopez Pousa, A., Grignani, G., Redondo, A., Hindi, N., Provenzano, S., Sebio, A., Lopez Martin, J. A., Valverde, C., Martinez Trufero, J., et al. (2025) · Cancer · doi:10.1002/cncr.35628 · Cited by 29
“Indeed, BS on average show very low TMB: 0.79–1.96 mutations/Mbase in osteosarcoma, 11,17–19 ~0.2 mutations/Mbas in Ewing sarcoma 19,20 and 5 mutations/Mbase in chondrosarcoma with some correlation with grade.”
InfluentialState-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma
Meazza, C., & Asaftei, S. D. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1936499 · Cited by 29
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4381 · Cited by 28
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Movva, S., Seier, K. P., Avutu, V., Banks, L. B., Chan, J. E., Chi, P., Dickson, M. A., Gounder, M. M., Kelly, C. M., Keohan, M. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2519 · Cited by 29
Self-citationSystemic strategies for osteosarcoma: advances and future directions
Morya, V. K., Magar, A. G., Park, S., & Noh, K.-C. (2025) · Discover Oncology · doi:10.1007/s12672-025-02208-9 · Cited by 28
What is the best clinical approach to recurrent/refractory osteosarcoma?
Meazza, C., Bastoni, S., & Scanagatta, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760848 · Cited by 28
Liu, Y., Liu, X., & Yang, S. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00163 · Cited by 28
Marec‐Bérard, P., Dalban, C., Gaspar, N., Brugières, L., Gentet, J., Lervat, C., Corradini, N., Castex, M., Schmitt, C., Pacquement, H., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.007 · Cited by 27
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma
Just, M. A., Mater, D. V., & Wagner, L. M. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29084 · Cited by 27
Riedel, R. F., Ballman, K. V., Lu, Y., Attia, S., Loggers, E. T., Ganjoo, K. N., Livingston, M. B., Chow, W. A., Wright, J. A., Ward, J. H., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0679 · Cited by 26
Self-citationCurrent approaches to management of bone sarcoma in adolescent and young adult patients
Ingley, K. M., Maleddu, A., Grange, F. L., Gerrand, C., Bleyer, A., Yasmin, E., Whelan, J., & Strauss, S. J. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29442 · Cited by 26
Berlanga, P., Ndounga‐Diakou, L. A., Aerts, I., Corradini, N., Ducassou, S., Strullu, M., Carli, É. D., André, N., Entz‐Werlé, N., Raimbault, S., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.21568 · Cited by 26
Ocular surface toxicities associated with modern anticancer therapies
Boucher, R. C., Haigh, O. L., Barreau, E., Champiat, S., Lambotte, O., Adam, C., Labétoulle, M., & Rousseau, A. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.10.002 · Cited by 26
Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment
Lei, Y. H., Junxin, C., Huang, Y., Xiaoguang, L., & Yu, B.-S. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100322 · Cited by 25
Challenges of Systemic Therapy Investigations for Bone Sarcomas
Nakano, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073540 · Cited by 25
Tyrosine kinase inhibitors in sarcoma treatment (Review)
Kyriazoglou, A. I., Gkaralea, L. E., Kotsantis, I., Anastasiou, Μ., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Nixon, I., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13303 · Cited by 25
Iwai, T., Oebisu, N., Hoshi, M., Orita, K., Yamamoto, A., Hamamoto, S., Kageyama, K., & Nakamura, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-66934-6 · Cited by 24
Pearson, A. D., Gaspar, N., Janeway, K., Campbell-Hewson, Q., Lawlor, E. R., Copland, C., Karres, D., Norga, K., Benzaghou, F., Weiner, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.008 · Cited by 22
Zhou, Y., Li, M., Zhang, B., Yang, C., Wang, Y., Zheng, S., Tang, L., Zhou, C., Qian, G., Huang, Y., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03132-x · Cited by 22
Eigenbrood, J., Wong, N. W., Mallory, P. W., Pereira, J. S., Williams, D., Morris-II, D. W., Beck, J. A., Cronk, J. C., Sayers, C. M., Mendez, M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3723 · Cited by 24
SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression
Lézot, F., Corre, I., Morice, S., Rédiní, F., & Verrecchia, F. (2020) · Cells · doi:10.3390/cells9030536 · Cited by 22
Advances in the Management of Pediatric Sarcomas
Tejada, F. N. H., Zamudio, A. G., Marques-Piubelli, M. L., Cuglievan, B., & Harrison, D. J. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00995-8 · Cited by 22
Recent advances in understanding osteosarcoma and emerging therapies
Gaspar, N., Costa, M. E. M. D., Fromigué, O., Droit, R., Berlanga, P., & Marchais, A. (2020) · Faculty Reviews · doi:10.12703/r/9-18 · Cited by 22
Felix, A., Berlanga, P., Toulmonde, M., Landman‐Parker, J., Dumont, S., Vassal, G., Deley, M. L., & Gaspar, N. (2021) · Cancer Medicine · doi:10.1002/cam4.3712 · Cited by 22
Martins‐Neves, S. R., Sampaio-Ribeiro, G., & Gomes, C. M. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911416 · Cited by 22
Huang, R., Xu, M., Guo, W., Cheng, M., Dong, R., Tu, J., Xu, S., & Zou, C. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03046-x · Cited by 21
Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
Tang, L., Niu, X., Wang, Z., Cai, Q., Tu, C., Fan, Z., & Yao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811687 · Cited by 21
Children's Oncology Group's 2023 blueprint for research: Bone tumors
Reed, D. R., Grohar, P. J., Rubin, E. M., Binitie, O. T., Krailo, M., Davis, J. L., DuBois, S. G., & Janeway, K. A. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30583 · Cited by 21
Self-citationIntegrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care
Kumar, R. R., Sporn, K., Khanna, A., Paladugu, P., Gowda, C., Ngo, A., Jagadeesan, R., Zaman, N., & Tavakkoli, A. (2025) · Diagnostics · doi:10.3390/diagnostics15111377 · Cited by 21
Smolle, M. A., Szkandera, J., Andreou, D., Palmerini, E., Bergovec, M., & Leithner, A. (2020) · EFORT Open Reviews · doi:10.1302/2058-5241.5.200069 · Cited by 19
Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma
Rutkowski, P. L. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00422-8 · Cited by 19
Targeting tumor microenvironment and metastasis in children with solid tumors
Wessel, K. M., & Kaplan, R. N. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001082 · Cited by 20
NOTCH Signaling in Osteosarcoma
Zhang, Z., Wu, W., & Shao, Z. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030146 · Cited by 19
Zhang, C., Wu, H., Xu, G., Xu, Y., Ma, W., Li, Z., & Zhang, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11024-9 · Cited by 19
HOXC13-driven TIMM13 overexpression promotes osteosarcoma cell growth
Han, Q., Yan, P., Song, R., Liu, F., & Tian, Q. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05910-0 · Cited by 19
van Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
Sorenson, L., Fu, Y., Hood, T., Warren, S. E., & McEachron, T. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629779 · Cited by 20
Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials
Cren, P., Lebellec, L., Ryckewaert, T., & Penel, N. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594445 · Cited by 19
Tharakan, S., Raja, I., Pietraru, A., Sarecha, E., Gresita, A., Petcu, E., Ilyas, A., & Hadjiargyrou, M. (2023) · Gels · doi:10.3390/gels9040274 · Cited by 18
Cesne, A. L., Chevreau, C., Perrin, C., Italiano, A., Hervieu, A., Blay, J., Piperno-Neumann, S., Saâda-Bouzid, E., Bertucci, F., Firmin, N., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101569 · Cited by 18
Whittle, S. B., Offer, K., Roberts, R. D., LeBlanc, A. K., London, C. A., Majzner, R. G., Huang, A. Y.-C., Houghton, P. J., Sweet-Cordero, A., Grohar, P. J., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29188 · Cited by 18
Self-citationPeretz Soroka, H., Vora, T., Noujaim, J., Marcoux, N., Cohen‐Gogo, S., Alcindor, T., Holloway, C., Rodrigues, C., Karachiwala, H., Alvi, S., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6515 · Cited by 17
Osteosarcoma: An Evolving Understanding of a Complex Disease
Alexander, J. H., Binitie, O. T., Letson, G. D., & Joyce, D. M. (2021) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-20-00838 · Cited by 17
Regorafenib for the Treatment of Sarcoma
Blay, J., Duffaud, F., George, S., Maki, R. G., & Penel, N. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00990-0 · Cited by 17
Self-citation
Metadata
- Authors
- Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, D. K., Riedel, R. F., Attia, S., Mascarenhas, L., & Maki, R. G.
- Affiliations
- Oregon Health & Science University (US)
- Cancer Research And Biostatistics (US)
- Stanford Cancer Institute (US)
- Fred Hutch Cancer Center (US)
- Sarcoma Oncology Center (US)
- Northwestern University (US)
- Levine Cancer Institute (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Indiana University Bloomington (US)
- Mayo Clinic (US)
- Sarcoma Alliance for Research through Collaboration (US)
- Duke Medical Center (US)
- University of Southern California (US)
- Northwell Health (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2019-06-01
- Volume
- 37
- Issue
- 16
- Pages
- 1424-1431
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC7799443
- OpenAlex
- W2941090871
- Cited by
- 268
- References
- 27
- Citations by year
- 2026: 27 · 2025: 29 · 2024: 35 · 2023: 52 · 2022: 36 · 2021: 44 · 2020: 35 · 2019: 9
- FWCI
- 22.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292, P30CA014089)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- regorafenib, metastatic osteosarcoma, multikinase inhibitor, progression-free survival, relapsed sarcoma, crossover design, overall survival, drug safety, colonic perforation
- MeSH terms
- Progression-Free Survival, Adolescent, Adult, Aged, Antineoplastic Agents, Bone Neoplasms, Double-Blind Method, Female, Humans, Male, Middle Aged, Phenylurea Compounds, Pyridines, Osteosarcoma, Time Factors, United States, Disease Progression, Cross-Over Studies, Protein Kinase Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
